Beta Bionics, Inc.
Beta Bionics, Inc. (Nasdaq: BBNX) is a medical device company that develops and commercializes insulin-delivery systems for people with diabetes who require insulin. Its commercial product, the iLet Bionic Pancreas, is an automated insulin-delivery system cleared in the United States for people with Type 1 diabetes… From the company’s description.
In fiscal 2025, Beta Bionics, Inc. reported revenue of $100.25M, up 53.9% from fiscal 2024, and a net loss of $73.20M. Its operating margin was −71.5%, and operations used $50.92M in cash. Over the twelve months to Sep 30, 2026, revenue was $127.27M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Beta Bionics, Inc. does
In the company’s own words
Beta Bionics, Inc. (Nasdaq: BBNX) is a medical device company that develops and commercializes insulin-delivery systems for people with diabetes who require insulin. Its commercial product, the iLet Bionic Pancreas, is an automated insulin-delivery system cleared in the United States for people with Type 1 diabetes aged six and older. It uses continuous glucose monitor data and adaptive algorithms to determine and deliver insulin doses, with users making qualitative meal announcements rather than calculating doses or counting carbohydrates. The system includes a pump, insulin cartridges, infusion sets, software, and a touchscreen interface, and integrates with compatible Dexcom and Abbott glucose monitors. The company sells in the United States through its direct commercial organization and distributors, supporting patients and healthcare providers with training and customer service. Beta Bionics also develops a tubeless patch pump and a bihormonal iLet system intended to deliver both insulin and glucagon. As of December 31, 2025, its installed base totaled 35,011 iLet devices.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- IRVINE, CA
- Fiscal year end
- December
- CIK
- 1674632
- SIC
- 3841
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Beta Bionics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Beta Bionics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Beta Bionics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Beta Bionics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Beta Bionics, Inc.'s last four quarterly filings that the numbers alone won't show?”